Plasmablastic lymphoma: current perspectives

References

• CampoESteinHHarrisNLPlasmablastic lymphomaWHO Classification of Tumors of Hematopoietic and Lymphoid TissuesSwerdlowSHCampoEHarrisNLLyon, FranceIARC Press2017321322
   Google Scholar
• HarrisNLJaffeESDieboldJWorld Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997J Clin Oncol199917123835384910577857
   PubMed Web of Science ®Google Scholar
• LiJZhaoSWangJChenJWenWZhangQCD20-negative diffuse large B cell lymphoma: a comprehensive analysis of 695 casesTumour Biol20163733619363726459310
   PubMedGoogle Scholar
• Montes-MorenoSGonzalez-MedinaARRodriguez-PinillaSMAggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotypeHaematologica20109581342134920418245
   PubMed Web of Science ®Google Scholar
• Montes-MorenoSMontalbánCPirisMALarge B-cell lymphomas with plasmablastic differentiation: a biological and therapeutic challengeLeuk Lymphoma201253218519421812534
   PubMed Web of Science ®Google Scholar
• DelecluseHJAnagnostopoulosIDallenbachFPlasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infectionBlood1997894141314209028965
   PubMed Web of Science ®Google Scholar
• MorscioJDierickxDNijsJClinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and post-transplant patients: single-center series of 25 cases and meta-analysis of 277 reported casesAm J Surg Pathol201438787588624832164
   PubMed Web of Science ®Google Scholar
• DongHYScaddenDTde LevalLPlasmablastic Lymphoma in HIV-Positive PatientsAm J Surg Pathol200529121633164116327436
   PubMed Web of Science ®Google Scholar
• SongMKChungJSShinHJClinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvementAnn Hematol201291569770322071570
   PubMed Web of Science ®Google Scholar
• Teruya-FeldsteinJChiaoEFilippaDACD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patientsAnn Oncol200415111673167915520070
   PubMed Web of Science ®Google Scholar
• LoghaviSAlayedKAladilyTNStage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patientsJ Hematol Oncol2015816526055271
   PubMed Web of Science ®Google Scholar
• CastilloJJBibasMMirandaRNThe biology and treatment of plasmablastic lymphomaBlood2015125152323233025636338
   PubMed Web of Science ®Google Scholar
• TchernonogEFauriePCoppoPClinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA groupAnn Oncol201728484384828031174
   PubMed Web of Science ®Google Scholar
• QunajLCastilloJJOlszewskiAJSurvival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data BaseLeuk Lymphoma20185961928629244
   PubMed Web of Science ®Google Scholar
• CastilloJJFurmanMBeltránBEHuman immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapyCancer2012118215270527722510767
   PubMed Web of Science ®Google Scholar
• ChapmanJGentlesAJSujoyVGene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programsLeukemia201529112270227325921246
   PubMed Web of Science ®Google Scholar
• ValeraABalaguéOColomoLIG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomasAm J Surg Pathol2011341116861694
   Web of Science ®Google Scholar
• BoguszAMSeegmillerACGarciaRShangPAshfaqRChenWPlasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literatureAm J Clin Pathol2009132459760519762538
   PubMed Web of Science ®Google Scholar
• ValeraAColomoLMartínezAALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangementsMod Pathol201326101329133723599149
   PubMed Web of Science ®Google Scholar
• Montes-MorenoSMartinez-MagunacelayaNZecchini-BarreseTPlasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1Mod Pathol20173018594
   PubMed Web of Science ®Google Scholar
• XiaYXu-MonetteZYTzankovALoss of PRDM1/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphomaLeukemia201731362563627568520
   PubMed Web of Science ®Google Scholar
• ColomoLLoongFRivesSDiffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entitiesAm J Surg Pathol200428673674715166665
   PubMed Web of Science ®Google Scholar
• HarmonCMSmithLBPlasmablastic lymphoma a review of clinicopathologic features and differential diagnosisArch Pathol Lab Med2016140101074107827684979
   PubMed Web of Science ®Google Scholar
• MariniCBaldaiaHTrigoFCastilloJJTransformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphomaAm J Hematol2016918E32427012155
   PubMed Web of Science ®Google Scholar
• CastilloJJWinerESStachurskiDClinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphomaLeuk Lymphoma201051112047205320919850
   PubMed Web of Science ®Google Scholar
• SchommersPWyenCHentrichMPoor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort studyAIDS201327584284523574794
   PubMed Web of Science ®Google Scholar
• CattaneoCReAUngariMPlasmablastic lymphoma among human immunodeficiency virus-positive patients: results of a single center’s experienceLeuk Lymphoma201556126726924712980
   PubMed Web of Science ®Google Scholar
• SchommersPWyenCHentrichMPoor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort studyAIDS201327584284523574794
   PubMed Web of Science ®Google Scholar
• PhippsCYeohKWLeeYSDurable remission is achievable with localized treatment and reduction of immunosuppression in limited stage EBV-related plasmablastic lymphomaAnn Hematol201796111959196028831541
   PubMed Web of Science ®Google Scholar
• ZelenetzADAbramsonJSAdvaniRHNon-Hodgkin’s LymphomasJ Natl Compr Canc Netw20108328833420202462
   PubMed Web of Science ®Google Scholar
• KoizumiYUehiraTOtaYClinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 casesInt J Hematol2016104666968127604616
   PubMed Web of Science ®Google Scholar
• ArmstrongRBradrickJLiuYCSpontaneous regression of an HIV-associated plasmablastic lymphoma in the oral cavity: a case reportJ Oral Maxillofac Surg20076571361136417577503
   PubMed Web of Science ®Google Scholar
• NastaSDCarrumGMShahabIHananiaNAUddenMMRegression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapyLeuk Lymphoma200243242342611999580
   PubMed Web of Science ®Google Scholar
• PinnixCCShahJJChuangHDoxorubicin-based chemotherapy and radiation therapy produces favorable outcomes in limited-stage plasmablastic lymphoma: a single-institution reviewClin Lymphoma Myeloma Leuk201616312212826795083
   PubMed Web of Science ®Google Scholar
• ZelenetzADGordonLIWierdaWGAbramsonJSAdvaniRHAndreadisCB-cell lymphomasNCCN Clin Pract Guidel OncolVersion 12017
   Google Scholar
• PatelKFengLOkiYPlasmablastic lymphoma: 28 patient single institution experienceBlood2013122214310 LP4310
   Google Scholar
• SparanoJALeeJYKaplanLDRituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaBlood2010115153008301620023215
   PubMed Web of Science ®Google Scholar
• ReACattaneoCMichieliMHigh-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapyJ Clin Oncol200321234423442814581441
   PubMed Web of Science ®Google Scholar
• LiuMLiuBLiuBHuman immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 casesOncol Rep20153341615162025695332
   PubMed Web of Science ®Google Scholar
• ReAMichieliMCasariSHigh-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factorsBlood200911471306131319451551
   PubMed Web of Science ®Google Scholar
• HamadaniMDevineSMReduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we canBlood2009114122564256619762505
   PubMed Web of Science ®Google Scholar
• Al-MalkiMMCastilloJJSloanJMReAHematopoietic cell transplantation for plasmablastic lymphoma: a reviewBiol Blood Marrow Transplant201420121877188424946718
   PubMed Web of Science ®Google Scholar
• LeonardJPKolibabaKReevesJARandomized phase 2 open-label study of R-CHOP ± bortezomib in patients (Pts) with untreated non-germinal center B-cell-like (Non-GCB) subtype diffuse large cell lymphoma (DLBCL): results from the Pyramid trial (NCT00931918)Blood201512623811
   Web of Science ®Google Scholar
• RobakTHuangHJinJBortezomib-based therapy for newly diagnosed mantle-cell lymphomaN Engl J Med20153721094495325738670
   PubMed Web of Science ®Google Scholar
• Guerrero-GarciaTAMogollonRJCastilloJJBortezomib in plasma-blastic lymphoma: a glimpse of hope for a hard-to-treat diseaseLeuk Res2017629121628963907
   PubMed Web of Science ®Google Scholar
• Fernandez-AlvarezRGonzalez-RodriguezAPRubio-CastroABortezomib plus CHOP for the treatment of HIV-associated plasmablas-tic lymphoma: clinical experience in three patientsLeuk Lymphoma201657246346625976108
   PubMed Web of Science ®Google Scholar
• CastilloJJReaganJLSikovWMWinerESBortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphomaBr J Haematol2015169335235525612847
   PubMed Web of Science ®Google Scholar
• DittusCGroverNEllsworthSTanXParkSIBortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysisLeuk Lymphoma20185992121212729303024
   PubMed Web of Science ®Google Scholar
• CastilloJJGuerrero-GarciaTBaldiniFBortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphomaBr J Haematol201813
   Web of Science ®Google Scholar
• FangCZhuDDongHLenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysisInt J Clin Exp Med201587107051071326379862
   PubMed Web of Science ®Google Scholar
• CarrasSRegnyCPeoc’hMDramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric nonhuman immunodeficiency virus-associated plasmablastic lymphomaLeuk Lymphoma201556102986298825676034
   PubMed Web of Science ®Google Scholar
• BibasMGrisettiSAlbaLPatient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide aloneJ Clin Oncol2012303120122014
   Google Scholar
• YanamandraUSahuKKJainNPrakashGSaikiaUMalhotraPPlasmablastic lymphoma: successful management with CHOP and lenalidomide in resource constraint settingsAnn Hematol201695101715171727324386
   PubMed Web of Science ®Google Scholar
• SchmitJMDelauneJNorkinMGrosbachAA case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapyOncol Res Treat201740124648
   Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• Forero-TorresAFanaleMAdvaniRBrentuximab vedotin in transplant-naive patients with relapsed or refractory Hodgkin lymphoma: analysis of two phase I studiesOncologist20121781073108022855426
   PubMed Web of Science ®Google Scholar
• PretscherDKalischAWilhelmMBirkmannJRefractory plasmablastic lymphoma-a review of treatment options beyond standard therapyAnn Hematol201796696797028011983
   PubMed Web of Science ®Google Scholar
• MineSHishimaTSuganumaAInterleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targetsSci Rep20177111128127051
   PubMed Web of Science ®Google Scholar
• KoenigGStevensTMPekerDPlasmablastic microlymphoma arising in human herpesvirus-8-associated multicentric Castleman disease in a human immunodeficiency virus-seronegative patient with clinical response to anti-interleukin-6 therapyHistopathology201567693093225900626
   PubMed Web of Science ®Google Scholar
• PerrineSPHermineOSmallTA phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignanciesBlood200710962571257817119113
   PubMed Web of Science ®Google Scholar
• CastilloJJReaganJLBishopKDAporEViral lymphomagenesis: from pathophysiology to the rationale for novel therapiesBr J Haematol2014165330031524533596
   PubMed Web of Science ®Google Scholar
• LaurentCFabianiBdoCImmune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patientsHaematologica2016101897698427175027
   PubMed Web of Science ®Google Scholar
• DarnellJETranscription factors as targets for cancer therapyNat Rev Cancer200221074074912360277
   PubMed Web of Science ®Google Scholar
• DelmoreJEIssaGCLemieuxMEBET bromodomain inhibition as a therapeutic strategy to target c-MycCell2011146690491721889194
   PubMed Web of Science ®Google Scholar
• PalumboAChanan-KhanAWeiselKDaratumumab, bortezomib, and dexamethasone for multiple myelomaN Engl J Med2016375875476627557302
   PubMed Web of Science ®Google Scholar
• DimopoulosMAOriolANahiHDaratumumab, lenalidomide, and dexamethasone for multiple myelomaN Engl J Med2016375141319133127705267
   PubMed Web of Science ®Google Scholar